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Hyperkalemia with ACE inhibitors 
plus aldosterone blockers in CKD
Preston et al., Hypertension 2009; 53: 754–760; doi:10.1161/ 
HYPERTENSIONAHA.108.125252
The addition of aldosterone receptor antagonists to treatments 
with angiotensin-converting enzyme inhibitors has been shown to 
benefit a variety of renal and cardiovascular conditions. However, 
in patients with impaired renal function, this therapeutic combina-
tion produces modest hyperkalemia, the pathogenesis of which has 
been unclear. To examine this question, Preston et al. investigated 
the effect of lisinopril plus spironolactone on potassium handling 
in hypertensive patients with renal impairment due to chronic kid-
ney disease (CKD). Under control conditions, CKD patients had 
serum potassium similar to that of normal controls. Interestingly, 
when the patients were given a 35-mmol oral potassium challenge, 
they maintained serum potassium in the same range as normal 
subjects, despite the fact that their renal excretion rate was mark-
edly impaired. This indicates that CKD is associated with more effi-
cient potassium disposal into cells or into other excretory avenues, 
such as stool (which had already been known) or sweat. It is well 
established that cellular uptake of potassium after an acute exog-
enous potassium load is markedly influenced by previous dietary 
history, with diets high in potassium increasing the effectiveness 
of cellular potassium uptake. Perhaps patients with CKD, because 
of their decreased renal potassium excretory capacity, respond in 
a manner similar to that of normal subjects fed high potassium. 
As shown in the Figure, in patients with CKD, dual therapy with 
lisinopril plus spironolactone increased plasma potassium con-
centration (by approximately 0.5 mmol/l). However, when given a 
35-mmol oral potassium challenge, patients receiving dual therapy 
excreted potassium almost as effectively as when given placebo; 
at the end of a 5-hour observation period, total renal potassium 
excretion was the same under both conditions. Because potential 
extrarenal avenues for potassium loss were not examined, con-
clusions from this study must be tentative. Nonetheless, because 
of the study’s short duration, its results strongly suggest that dual 
renin–angiotensin and aldosterone blockade impairs transcellular 
potassium disposition. Several mechanisms could account for this 
result, and additional work appears warranted.
Juan Oliver
Stent placement in patients with 
atherosclerotic renal artery stenosis 
and impaired renal function
Bax et al., Ann Intern Med advance online publication 4 May 2009 
Controversy exists over the utility of renal artery angioplasty and 
stenting. Observational studies and trials occasionally support 
but more often fail to support intervention in renal artery narrow-
ing by atherosclerosis. Significant discussion has focused on the 
baseline assumptions of what is the relevant outcome for trials in 
renal artery interventions.
A new randomized trial compares stent placement with medical 
therapy in 140 patients with impaired renal function and ostial 
renal artery stenosis at ten European centers. Patients received 
medication only along with treatment for atherosclerotic risk fac-
tors or medical therapy plus a stent in every ostial stenosis. Sub-
jects were followed every 3 months for 2 years, and their serum 
creatinine level was measured. The primary end point was pro-
gression of kidney disease defined as a loss of 20% or greater in 
estimated creatinine clearance. Only 46 of 64 subjects randomized 
to stent placement had a stenosis confirmed by angiography and 
underwent angioplasty and stent placement. Reaching the pri-
mary end point, 22 subjects in the medication group and 16 sub-
jects in the stent group experienced a greater than 20% decline 
in kidney function. Notably, two of the subjects reaching the end 
point in the stent group did not receive a stent at the beginning 
of the trial. There were no significant differences between groups 
with respect to either cardiovascular morbidity or mortality or 
blood pressure control. Complications of the renal artery pro-
cedures included two procedure-related deaths related to perfo-
rated renal arteries. The authors conclude that stent placement 
with medical treatment had no clear effect on the progression of 
impaired kidney function.
Trials assessing the impact of renal artery stenting have dif-
fered and perhaps struggled with the choice of the appropriate 
end point. Loss of kidney function over time is clearly an appro-
priate and relevant end point. However, one must consider that 
renal artery angioplasty can be performed for other reasons, such 
as blood pressure control. Although this and other trials dem-
onstrate that in all-comers, stent placement does not delay pro-
gression of kidney disease, the physiology of renal artery lesions 
makes this an incredibly difficult disease to study. The changes 
in renal blood flow during the progression of a unilateral artery 
stenosis on the contralateral side may result in a failure to improve 
overall kidney function in spite of loss of function on the diseased 
side. Further trials should examine how the impact of unilateral 
versus bilateral disease should affect the choice of outcome. Also, 
the use of screening tests rather than an angiogram to identify 
subjects by their intention-to-treat category dilutes any potential 
treatment effect at present. Clinical trials of renal artery stenosis 
recurrently fail to demonstrate a benefit in the intention-to-treat 
analysis. However, the indication for intervention, the anatomy 
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with lisinopril plus spironolactone versus placebo.
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of the atherosclerosis, and the potential effect of its correction on 
physiology will continue to be important considerations.
Lynda Szczech
Midkine regulates  
the renin–angiotensin system
Hobo et al., J Clin Invest 2009; 119: 1616–1625; doi:10.1172/JCI37249
The midkine family of growth factors consists of two members, 
midkine and pleiotrophin, which share receptors and many char-
acteristics, such as heparin binding. Both growth factors have been 
implicated in a variety of biological functions, including mitogenic, 
antiapoptotic, transforming, angiogenic, chemotactic, and fibrino-
lytic functions. They are involved in development and repair of vari-
ous tissues, especially nerves, and midkine can be a neurotrophic 
factor for damaged peripheral nerves. They are also believed to be 
involved in the pathogenesis of cancer and inflammatory processes 
and in the kidney; midkine has been implicated in reperfusion- and 
cisplatin-induced renal injury as well as diabetic glomerulosclerosis. 
It was recently reported that mice with deletion of the pleiotrophin 
or the midkine gene had marked changes in the expression of several 
genes of the renin–angiotensin system in the aorta; expression of renin 
and angiotensinogen increased, and that of angiotensin-converting 
enzyme (ACE) decreased. The biological significance of these changes 
has remained obscure. Hobo et al. now address this question in the 
hypertension and renal damage that follow 5/6 nephrectomy. The 
authors found that whereas 5/6 nephrectomy induced hypertension 
in normal mice (Mdk+/+), mice with deleted midkine gene (Mdk–/–) 
had almost normal blood pressure. Similarly, the associated renal 
failure was significantly worse in Mdk+/+ mice as they showed more 
severe glomerular sclerosis (Figure). Very interestingly, the increased 
plasma angiotensin II after 5/6 nephrectomy seen in Mdk+/+ mice 
was absent in Mdk–/– mice. Moreover, while renal ACE expression 
was unchanged in Mdk+/+ mice, in the lung, ACE expression and 
activity was increased. Midkine expression and concentration were 
increased in the lung and plasma. Further, ACE expression in primary 
cultured human lung microvascular endothelial cells was increased 
by midkine. When this protein was given to midkine-deficient 
mice, it restored ACE expression in the lung and hypertension after 
5/6 nephrectomy. Oxidative stress might be involved in midkine 
expression, as nicotinamide adenine dinucleotide (NADH)/NADH 
phosphate oxidases in the lung increased after 5/6 nephrectomy and 
the antioxidative reagent tempol reduced midkine expression and 
plasma angiotensin II and ameliorated hypertension. These provoca-
tive results indicate that midkine regulates ACE and thus the activity of 
the renin–angiotensin system. In addition, midkine may be an impor-
tant factor in the pathogenesis of the hypertension of renal failure.
Juan Oliver
Genetic susceptibility  
to HIV nephropathy
Papeta et al., J Clin Invest 2009; 119: 1178–1188; doi:10.1172/JCI37131
Studies in humans and murine models have implicated defects in 
podocytes as critical factors in development of many glomerular 
diseases. Mutations in podocyte-expressed genes (for example, 
NPHS2, NPHS1, and MYH9) are associated with several sporadic 
renal diseases as well as HIV-1-associated nephropathy (HIVAN). 
The combination of gene expression profiling and linkage analysis 
(expression quantitative trait locus (eQTL) mapping) has been used to 
elucidate molecular pathways downstream of mutations causing dis-
ease. Identifying loci that influence both clinical phenotypes and tran-
script abundance may uncover molecular pathways that link sequence 
variation to disease. To elucidate the mechanisms accounting for the 
genetic susceptibility to HIVAN, Papeta et al. applied eQTL analy-
sis of podocyte genes in HIV-1 transgenic mice. By genetic linkage 
analysis of two independent crosses of mouse strains with contrast-
ing susceptibility to HIVAN, the authors found that Nphs2 transcript 
levels were heritable and controlled by an ancestral cis-eQTL on chro-
mosome 1 that produced reactive changes in other podocyte genes: 
Myh9, Nphs1, Kirrel, and Synpo. In addition, Nphs2 expression was 
found to be controlled by two trans-eQTLs localized to nephropa-
thy susceptibility intervals (the previously reported HIVAN1 and the 
newly identified HIVAN2 loci on chromosome 3 and chromosome 
13, respectively), strongly suggesting that the genes influencing Nphs2 
transcript abundance and nephropathy are the same. Interestingly, 
transregulation of podocyte genes by the HIVAN loci was observed 
in the absence of HIV-1 or glomerulosclerosis, a finding confirmed in 
HIVAN1 and HIVAN2 congenic/consomic mice. The identification of 
distinct but related molecular phenotypes for HIVAN1 and HIVAN2 
suggests that the underlying susceptibility genes introduce different 
lesions within common regulatory pathways. The authors also found 
that the podocyte expression profile was additionally altered in the 
presence of HIV-1 and HIVAN1 susceptibility alleles, demonstrating 
gene–environment interaction. These data suggest that transcript lev-
els of Nphs2 and related podocyte genes interact in a network, and that 
HIVAN susceptibility genes introduce genetic lesions that, by perturb-
ing regulatory pathways and appropriate transcriptional responses to 
HIV-1, produce susceptibility to nephropathy. This important study 
elucidates the molecular networks that connect diverse glomerulopa-
thy-associated genes. In addition, the identification of podocyte tran-
sregulators and their associated network may provide insight into the 
pathogenesis of multiple forms of nephropathy.
Juan Oliver
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5/6 Nephrectomy induces hypertension that is prevented in mice with 
midkine gene deletion. Representative glomerular histology shows that 
Mdk–/– mice had less glomerular sclerosis. SBP, systolic blood pressure. 
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